Acelyrin, Inc.

Equities

SLRN

US00445A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.68 ^USD	-4.10%		+7.59%	-37.27%

May. 09	Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	CI
May. 09	Acelyrin, Inc. Announces CEO Changes	CI

Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 04:22 pm EDT

Acelyrin, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 381.64 million compared to USD 64.77 million a year ago. Basic loss per share from continuing operations was USD 5.43 compared to USD 41.59 a year ago.

Latest news about Acelyrin, Inc.

Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	May. 09	CI
Acelyrin, Inc. Announces CEO Changes	May. 09	CI
Acelyrin, Inc. Announces Leadership Transition	May. 09	CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating	Mar. 21	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20	MT
Sector Update: Health Care	Mar. 20	MT
Acelyrin Shares Rise After Lonigutamab Shows Clinical Responses in Thyroid Eye Disease Trial	Mar. 20	MT
Transcript : Acelyrin, Inc. - Special Call	Mar. 20
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	Mar. 20	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Mar. 11	MT
Acelyrin's Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis Meets Primary Endpoint; Shares Rise	Mar. 11	MT
Acelyrin, Inc. Announces Positive Top-Line Results from Its Global Phase 2B/3 Clinical Trial of Izokibep in Psoriatic Arthritis	Mar. 11	CI
Acelyrin, Inc. Announces Long-Term 32-Week Data from the Phase 2B Trial of Izokibep in Hidradenitis Suppurativa	Mar. 11	CI
Madrigal Pharmaceuticals Names New CFO	Feb. 28	MT
Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications	Feb. 15	CI
Acelyrin, Inc. Appoints Lynn Tetrault to Board of Directors	Dec. 20	CI
Acelyrin, Inc.(NasdaqGS:SLRN) added to NASDAQ Biotechnology Index	Dec. 18	CI
Acelyrin, Inc.(NasdaqGS:SLRN) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Wells Fargo Starts Coverage on ACELYRIN with Equalweight Rating, $11 Price Target	Dec. 13	MT
Citigroup Initiates ACELYRIN at Neutral Rating With $8 Price Target	Dec. 08	MT
US Equity Markets Close Higher Tuesday After Fed Governors' Comments	Nov. 28	MT

Chart Acelyrin, Inc.

Duration

Period

More charts

Company Profile

ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Companyâs lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.68 USD

Average target price

22.5 USD

Spread / Average Target

+380.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACELYRIN, INC.	-37.27%	463M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs